阿拉马尔生物科学公司、阿尔茨海默病数据倡议组织和盖茨创投联合成立全球合作伙伴关系，推动阿尔茨海默病的转化研究-动脉网

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.

CISION 等信源发布 2025-06-10 21:12



可切换为仅中文







Multi-center project will profile over 40,000 samples

多中心项目将对超过40,000个样本进行分析建档。

using ultra-sensitive NULISA™ technology.

使用超灵敏的NULISA™技术。

FREMONT, Calif.

加利福尼亚州弗里蒙特

，

June 10, 2025

2025年6月10日

/PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, the Alzheimer's Disease Data Initiative and Gates Ventures today announced a strategic partnership with the goal to generate one of the largest proteomic datasets linked to clinical outcomes in Alzheimer's Disease (AD).

/PRNewswire/ -- Alamar Biosciences是一家致力于推动精准蛋白质组学以实现疾病最早检测的公司，与阿尔茨海默病数据倡议组织和Gates Ventures今天宣布了一项战略合作，目标是生成一个与阿尔茨海默病（AD）临床结果相关联的最大蛋白质组数据集之一。

This international project will profile over 40,000 plasma samples representing AD and related dementias using Alamar's ultra-sensitive .

这个国际项目将使用Alamar的超灵敏技术对代表阿尔茨海默病及相关痴呆症的40,000多个血浆样本进行分析。

NULISA™ technology

NULISA™ 技术

, with the goal of accelerating biomarker discovery and driving new insights into the progression and treatment of AD.

，目标是加速生物标志物的发现，并推动对阿尔茨海默病进展和治疗的新见解。

继续阅读

Alzheimer's Disease Data Initiative

阿尔茨海默病数据倡议

Gates Ventures

盖茨创投

'This collaboration reflects our shared commitment to transform the landscape of Alzheimer's research through data, technology, and global partnerships,'

“此次合作体现了我们通过数据、技术和全球合作伙伴关系来改变阿尔茨海默病研究领域的共同承诺。”

said

说

Yuling Luo

骆玉玲

, PhD, Founder, Chairman and CEO of Alamar Biosciences.

博士，Alamar Biosciences创始人、董事长兼首席执行官。

'By combining our NULISA platform with Alzheimer's Disease Data Initiative's infrastructure and Gates

“通过将我们的NULISA平台与阿尔茨海默病数据倡议的基础设施和盖茨

Venture's

风险投资的

mission-driven investment, we aim to catalyze a new era of biomarker-driven discovery and therapeutic development.'

以使命为导向的投资，我们旨在开启一个由生物标志物驱动的发现和治疗开发的新时代。

As part of the initiative, Alamar's

作为该倡议的一部分，阿拉马尔的

NULISAseq™ CNS Disease Panel 120

NULISAseq™ 中枢神经系统疾病panel 120

and

和

Inflammation Panel 250

炎症面板 250

will be implemented at research centers in

将在研究中心实施

the United States

美国

，

Sweden

瑞典

，

United Kingdom

英国

, and

，以及

India

印度

. These panels deliver unparalleled sensitivity and specificity, enabling the accurate measurement of hundreds of brain- and immune-related proteins from just a small volume of blood or cerebrospinal fluid. A key feature of the CNS panel is its unique ability to distinguish brain-derived phosphorylated tau from total phosphorylated tau in blood—a critical advancement for the development of community-based screening programs.

这些面板提供了无与伦比的灵敏度和特异性，能够从小体积的血液或脑脊液中准确测量数百种大脑和免疫相关的蛋白质。CNS 面板的一个关键特性是它能够区分血液中的脑源性磷酸化 tau 和总的磷酸化 tau——这是开发基于社区的筛查计划的关键进展。

The resulting proteomic data will be integrated with clinical and longitudinal outcome measures and shared with the global research community by leveraging the .

生成的蛋白质组学数据将与临床和纵向结果指标相结合，并通过利用该平台与全球研究界共享。

Global Neurodegeneration Proteomics Consortium

全球神经退行性病变蛋白质组学联盟

's (GNPC) secure data-sharing processes.

（GNPC）的安全数据共享流程。

'Understanding the biological underpinnings of Alzheimer's Disease is essential for developing effective

理解阿尔茨海默病的生物学基础对于开发有效的

treatments,'

治疗，'

said

说

Niranjan Bose

尼兰詹·博斯

, Managing Director of Health & Life Sciences at Gates Ventures and interim Executive Director of the Alzheimer's Disease Data Initiative.

，盖茨风险投资公司健康与生命科学董事总经理，阿尔茨海默病数据倡议组织的临时执行董事。

'This initiative will provide a rich resource to researchers worldwide and help overcome long-standing barriers in early detection and stratified interventions.'

“这项举措将为全球研究人员提供丰富的资源，并有助于克服早期检测和分层干预中长期存在的障碍。”

This initiative represents a major step forward in building a comprehensive, clinically annotated Alzheimer's plasma proteome atlas, with the potential to unlock new biomarkers for diagnosis, prognosis, and therapeutic response. This strategic collaboration complements the efforts of the GNPC, which has brought together top dementia researchers and datasets to collaborate and create one of the largest disease-specific proteomics datasets ever assembled.

这项倡议代表着在构建全面的、临床注释的阿尔茨海默病血浆蛋白质组图谱方面迈出了重要的一步，有望揭示用于诊断、预后和治疗反应的新生物标志物。这一战略性合作补充了GNPC的努力，该中心汇集了顶尖的痴呆症研究人员和数据集，共同创建了有史以来规模最大的疾病特异性蛋白质组学数据集之一。

The project also emphasizes inclusivity by incorporating diverse cohorts from multiple geographic and ethnic populations..

该项目还通过纳入来自多个地理和种族群体的不同队列来强调包容性。

About the Alzheimer's Disease Data Initiative

关于阿尔茨海默病数据倡议组织

The Alzheimer's Disease Data Initiative is a coalition of leading academic, advocacy, government, industry, and philanthropy organizations that recognizes the need for dementia researchers to find easier ways to share data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments, and cures for Alzheimer's disease and related dementias.

阿尔茨海默病数据倡议是一个由领先的学术、倡导、政府、行业和慈善组织组成的联盟，认识到痴呆症研究人员需要找到更便捷的方式来共享数据、分析工具和科学发现。这些合作伙伴正在共同努力，加速推进阿尔茨海默病及相关痴呆症的新诊断方法、治疗手段和治愈方案的进展。

Learn more about the Alzheimer's Disease Data Initiative at .

了解有关阿尔茨海默病数据计划的更多信息，请访问。

www.alzheimersdata.org

。

About Alamar Biosciences, Inc.

关于阿拉马生物科学公司

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today.

Alamar Biosciences是一家私营的生命科学公司，致力于推动精准蛋白质组学的发展，以实现疾病的最早期检测。公司专有的NULISA平台与ARGO™ HT系统无缝结合基因组学的最新进展，达到个位数阿托摩尔级的检测灵敏度，远远超越了当前市场上最敏感的蛋白质检测技术。

For more information, please visit .

有关更多信息，请访问。

alamarbio.com

阿拉马尔生物公司

SOURCE Alamar Biosciences, Inc.

来源：Alamar Biosciences, Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+